Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (ISRCTN11217072) titled 'Phase I Trial: Quotient Code QSC301789' on Oct. 24.
Study Type: Interventional
Study Design:
First-in-man single ascending dose single-centre randomized study to assess the pharmacokinetics safety and tolerability in 48 healthy volunteers (Other)
Primary Sponsor: Larkspur Biosciences
Condition:
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Other
Intervention:
The sponsor has confirmed that the trial meets the criteria for deferral of public...